NYSE: BMY · General Drug Manufacturers

Bristol-Myers Squibb (BMY) fair value: undervalued or overvalued?

As of 14 Nov 2026, Faircurve's model values Bristol-Myers Squibb (BMY) at $68.95 a share. The stock last closed at $62.93, which puts the model's fair value 9.6% above the price. On the model's bands that reads as Fairly valued.

Revalued . Price is the close of 16 Nov 2026. Bristol-Myers Squibb Company.

The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.

Model fair value$68.95midpoint of 2,000 simulations
Last close$62.93NYSE: BMY
Gap to fair value+9.6%fair value against price
Model verdictFairly valuedevidence grade: Medium

This week, in three parts

What happenedThe run of 14 Nov 2026 moved the fair value from $69.69 to $68.95 (-1.1%). The model's quality adjustment to the peer multiple moved, lowering the fair value: most of the move.

What the model makes of itThe price of $62.93 is 9.6% below it: Fairly valued, on a medium evidence grade.

What's nextNext report on 4 Feb 2027. Options prices imply a move of about 10% either way over the next month. The next weekly run is on Saturday 21 Nov 2026.

What price range does the model give BMY?

The calibrated range for BMY over 63 trading days is $56.25 to $70.81. It sits around the last close, and its width comes from the volatility that BMY's own options imply (34% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.

The model's own simulated range, from the 20th to the 80th percentile of its runs, is $44.88 to $100.79. In 56% of the simulations the fair value came out above the price the model ran on.

$24.57$167.80
Spread of the 2,000 simulated fair values. Solid line: the midpoint, $68.95. Dashed line: the last close, $62.93.

Faircurve Insights · 14 Nov 2026

Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio.

Faircurve's model put the fair value of Bristol-Myers Squibb Company (BMY) at $68.95 a share on 14 Nov 2026. The previous run, on 7 Nov 2026, gave $69.69; the fair value moved -1.1%. The reason, in the model's words: "The model's quality adjustment to the peer multiple moved, lowering the fair value: most of the move." The calibrated range over 63 trading days is $56.25 to $70.81, built from the stock's own option-implied volatility and calibrated weekly against realised prices. Across 8,038 past valuations, ranges built this way held the price 60% of the time at this horizon. The evidence grade is Medium. It looks at input completeness, comparable companies and the width of outcomes, and does not say whether the fair value is right.

Bristol-Myers Squibb scores 34 out of 100 on quality against comparable companies. Two factors stand out most. Stability scores 0, with EBITDA margin downside volatility of 12.0 pts over five years against a peer median of 5.5 pts. Growth quality scores 31, with trailing revenue growth of -0.2% against a peer median of 6.0%. The model compares it with eight companies, including Pfizer Inc. (PFE) and Eli Lilly and Company (LLY).

Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.

The Global Pulse

Faircurve's note after each US session, in your inbox. No account needed.

When does BMY report earnings, and how has the stock reacted?

Bristol-Myers Squibb's next earnings report is scheduled for 4 Feb 2027. Companies can move their dates.

Options prices on 16 Nov 2026 imply a move of about 4.8% in either direction through the nearest expiry, about 10 days out. That is the size the market is pricing, not a direction. BMY's 30 day implied volatility works out to about 9.8% over one month.

Around its last 8 reports: what the options market priced, and what followed

Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across BMY's last 8 reports, ignoring direction, was 3.7%.

0%5%10%5.7%4.8%6 Feb '256.6%1.3%24 Apr '255.5%3.8%31 Jul '256.4%8.1%30 Oct '255.1%7.6%5 Feb '265.6%1.1%30 Apr '265.3%3.5%30 Jul '266.1%3.2%29 Oct '26priced before the reportthe move that followed
What the options market priced for each report, against the size of the move that followed. Priced: the move implied by options expiring after the report, on the last quote before it. Followed: the close before the report to the close after. Sizes only, no direction.

What the options market has priced for a month's move in BMY

0%5%10%15%29 Oct '26 report30 Jul '26 report30 Apr '26 report5 Feb '26 report10% at 16 Nov '2614 Nov '2516 Nov '26
What the options market priced for a month's move (30-day implied volatility, scaled to one month). It read 11% on 14 Nov 2025, reached 12% on 21 Nov 2025 and reads 10% on 16 Nov 2026. The marks are report dates.

How does BMY score on business quality?

Bristol-Myers Squibb's overall quality score is 34 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.

FactorScore (0 to 100)Headline measurePeer median
ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend.3318.1%ROIC20.2%
Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash).471.00xFCF / net income0.85x
Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes.31-0.2%Revenue growth, trailing6.0%
Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks.560.1%Net buybacks / market value0.9%
Balance sheetNet debt to EBITDA and interest coverage.332.33xNet debt / EBITDA1.21x
StabilityDownside volatility of the EBITDA margin over the last five years.012.0 ptsEBITDA margin downside volatility, 5y5.5 pts

How does BMY compare with similar companies?

The companies in general drug manufacturers closest to Bristol-Myers Squibb in market value, each on the same model and the same date.

CompanyLast closeModel fair valueGapModel verdict
PFE Pfizer Inc.$28.86$33.13+14.8%Fairly valued
GILD Gilead Sciences, Inc.$167.58$219.16+30.8%Undervalued
AMGN Amgen Inc.$462.32$479.14+3.6%Fairly valued
MRK Merck & Co., Inc.$144.46$126.11-12.7%Fairly valued
BIIB Biogen Inc.$251.65$256.53+1.9%Fairly valued
ABBV AbbVie Inc.$294.55$298.37+1.3%Fairly valued
JNJ Johnson & Johnson$282.55$226.25-19.9%Overvalued
LLY Eli Lilly and Company$1,431.67$1,125.83-21.4%Overvalued

What the comparable companies' multiples alone would give for BMY, the peer-implied price, is $75.62 a share on this run. The fair value weighs that against the company's own multiple.

All general drug manufacturer stocks ranked by gap to fair value

Bristol-Myers Squibb at a glance

Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio.

Market value
$129.7B
Sector
Healthcare
Industry
General Drug Manufacturers
Revenue expected, next twelve months
$49.0B
Consensus revenue growth, next fiscal year
+4.1%
Analysts with estimates
16
Beta to the US market
0.12
First valued by Faircurve
1 May 2026

At the close of 16 Nov 2026, 56.8% of the 1,085 graded US stocks the model covers traded below the model's fair value. BMY was among them.

How the fair value is worked out: the model prices Bristol-Myers Squibb on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.

What changed in the latest valuation?

On 7 Nov 2026 the model's fair value for BMY was $69.69. As of 14 Nov 2026 it is $68.95, a change of -1.1%. The model's quality adjustment to the peer multiple moved, lowering the fair value: most of the move. The model revalues every stock it covers each week, and again after an earnings report.

Questions about Bristol-Myers Squibb's valuation

Is Bristol-Myers Squibb stock undervalued or overvalued?

On Faircurve's model, BMY reads as Fairly valued as of 14 Nov 2026. The model's fair value is $68.95 a share against a last close of $62.93, a gap of +9.6%.

What is BMY's fair value?

$68.95 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $44.88 to $100.79.

What price range does the model give BMY?

$56.25 to $70.81 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.

When does Bristol-Myers Squibb report earnings next?

The next report is scheduled for 4 Feb 2027. Companies can move their dates.

How much has BMY moved on past earnings reports?

Across its last 8 reports the median two session move was 3.7%, ignoring direction. The largest was +8.1% around the report of 30 Oct 2025.

How confident is the model in this valuation?

The model's evidence grade for BMY is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.

The model's own ideas on BMY

The model holds no idea open on BMY today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on BMY with their outcomes. A free account is enough.

Keep reading